4Zhang W,Doherty M,Pascual E,et al.EULAR evidence based recommendations for gout.PartⅡ:management.Report of a task force of the Standing Committee for Interna-tional Clinical Studies Including Therapeutics(ESCISIT)[J].Ann Rheum Dis,2006,65(10):1312.
5Ernst ME,Fravel MA.Febuxostat:a selective xanthineoxi-dase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout[J].Clinical Therapeutics,2009,31(11):2503.
6Khosravan R,Grabowski BA,Wu JT,et al.Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects[J].Br J CIin Pharmacol,2008,65(3):355.
8Hamburger M,Baraf HS,Adamson TC,et al.Recommen-dations for the diagnosis and management of gout and hyperuricemia[J].Postgrad Med,2011,123(6Suppl1):3.
10Takeda Pharmaceuticals North America,Inc.ULORIC(fe-buxostat):prescribing information[EB/OL].[2011-01-22].http://general.takedapharm.com/content/file/PI.pdf?appli-cationCode=3f8eb050-0baf-42e3-905f-d1f406875b9c&fi-leTypeCode=ULORICPI.
二级参考文献78
1CHOI HK, MOUNT DB, REGINATO AM. Pathogenesis of gout [J]. Ann Intern Med, 2005, 143(7): 499-516.
2OKAMOTO K, EGER BT, NISHINO T, et al. An extremely potent inhibitor of xanthine oxidoreduetase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition[J]. J Biol Chem, 2003, 278(3) : 1848-1855.
3SCHLESINGER N. Management of acute and chronic gouty arthritis: present state-of-the-art[J]. Drugs, 2004, 64 (21) : 2399- 2416.
4HOSKISON KT, WORTMANN RL. Management of gout in older adults: barriers to optimal control[J]. Drugs Aging, 2007, 24 (1): 21-36.
6SCHUMACHER HR, BECKER MA, WORTMANN RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28- week, phase Ⅲ, randomized, double-blind, parallel-group trial [J]. Arthritis Rheum, 2008, 59(11 ) : 1540-1548.
7SCHUMACHER HR Jr, BECKER MA, LLOYD E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study[J]. Rheumatology (Oxford), 2009, 48 (2) : 188-194.
8Takano Y,Hase-Aoki K,Horiuchi H,et al.Selectivity of febuxostat,a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.Life Sci,2005,76(16):1835-1847.
9Bruce SP.Febuxostat:a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.Ann Pharmacother,2006,40(12):2187-2194.
10Mayer MD,Khosravan R,Vernillet L,et al.Pharmacokinetics and pharmacodynamics of febuxostat,a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.Am J Ther,2005,12(1):22-34.
3Zamudio-Cuevas Y, Hernfindez-Diaz C, Pineda C, et al. Molecular basis of oxidative stress in gouty arthropathy[J]. Clin Rheumatol, 2015, 34(10): 1667-1672.
4Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gou[J]. Arthritis Rheum, 1977, 20(3): 895-900.
5Roddy E, Doherty M. Epidemiology of gout[J]. Arthritis Res Ther, 2010, 12(6): 223.
6Garcia-Gonz~ilez A, Gaxiola-Robles R, Zenteno-Savin T. Oxidative stress in patients with rheumatoid arthritis[J]. Rev Invest Clin, 2015, 67(1): 46-53.
7Akimoto T, Morishita Y, Ito C, et al. Febuxostat for hyperuricemia in patients with advanced chronic kidney disease[J]. Drug Target Insights, 2014, 13(8): 39-43.
